Bangkok Genomics Innovation PCL (BKGI)

Bangkok Genomics Innovation Public Company Limited provides clinical and genomics services in Thailand. The company offers non-invasive prenatal testing which includes screening for fetal chromosomal abnormalities under the NIFTY brand; and genetic disease carrier screening testing services, such as screening before embryo implantation, carriers of genetic disease, and detection of gene abnormalities associated with thalassemia anemia under the VISTA brand. It also provides real time-PCR test for COVID-19, antigen testing of the COVID-19, SARS-CoV-2 serology testing, SARS-CoV-2 neutralizing antibody testing, and real time-PCR for monkeypox virus testing, as well as HPV DNA test; colon cancer testing under the COLOTECH brand; and individual genetic testing services under the DNALL brand. In addition, the company offers technology solution services, including DNA base sequencing, RNA base sequencing, and metabolism and protein omics tests. Further, it distributes PCR covid-19 test kits, personal protective equipment, and vital transport media. Additionally, the company offers health analytic and medical care services; and develops biotechnology products, as well as offers hydraulic excavators, tractors, wheel loaded air compressor, and spare parts. Furthermore, it is involved in retail business of pharmaceutical products, as well as operates education center and engaged in research activity. The company is involved in real estate business development business. Bangkok Genomics Innovation Public Company Limited was founded in 2017 and is headquartered in Bangkok, Thailand.